Research
MDMA como facilitador terapêutico: o impacto na reintegração de experiências traumáticas
DELOS Desarrollo Local Sostenible – November 12, 2025
Summary
MDMA-assisted psychotherapy shows promising potential for treating Post-Traumatic Stress Disorder (PTSD), with nine clinical trials reviewed indicating significant symptom reduction. Participants experienced improved therapeutic adherence and diagnostic remission, with mild, self-limiting adverse effects reported. Notably, no signs of substance abuse emerged in controlled settings. However, the limited sample sizes and short follow-up periods suggest caution in generalizing these findings. Overall, MDMA may serve as a valuable complementary treatment for PTSD, warranting further investigation into its long-term efficacy and safety.
Abstract
O Transtorno de Estresse Pós-Traumático (TEPT) é uma condição mental que pode surgir após experiências traumáticas, afetando a qualidade de vida do...
Effectiveness of ketamine/esketamine in alleviating postoperative fatigue: a systematic review
International Journal of Clinical Pharmacy – November 12, 2025
Summary
Ketamine and esketamine show promise in reducing postoperative fatigue (POF) after major abdominal surgeries, with a notable effect observed across various studies. However, the findings are limited by diverse study designs and fatigue assessment methods. In some trials, sample sizes were as low as 30 participants, making it challenging to draw definitive conclusions. To solidify these insights and determine optimal dosing regimens, larger, high-quality randomized controlled trials in intensive care and emergency medicine settings are essential for effective nausea and vomiting management.
Abstract
Current evidence suggests that ketamine/esketamine may be effective in alleviating POF, particularly in major abdominal surgeries. These findings s...
Dimethyltryptamine and harmine, components of ayahuasca, prevented cocaine-induced apoptosis in SH-SY5Y human neuroblastoma cells
Archives of Toxicology – November 12, 2025
Summary
No Summary
Abstract
Abstract not available from OpenAlex
Psychedelics produce enduring behavioral effects and functional plasticity through mechanisms independent of structural plasticity
Neuropsychopharmacology – November 12, 2025
Summary
No Summary
Abstract
Abstract not available from OpenAlex
Acute Kidney Failure and Myocarditis Triggered by Magic Mushroom Toxicity in a Patient With Prior Cocaine Exposure
Cureus – November 12, 2025
Summary
Magic mushroom poisoning can lead to severe acute kidney injury (AKI) and ischemic acute tubular necrosis, as evidenced by a case involving a middle-aged man with a history of cocaine use. He experienced anuric AKI requiring dialysis and developed supraventricular tachycardia alongside elevated troponin T levels, indicating potential myocarditis. Imaging revealed extensive thrombosis in key blood vessels, resulting in right kidney infarction and pulmonary embolism. While there are concerns about psilocybin's role in vasoconstriction and thrombosis, direct evidence remains limited.
Abstract
Magic mushroom poisoning can be associated with acute kidney injury (AKI), primarily due to ischemic acute tubular necrosis (ATN). Additionally, th...
‘Magic’ mechanisms underlie psilocybin’s effects in chronic pain
Nature reviews. Neuroscience – November 11, 2025
Summary
No Summary
Abstract
Abstract not available from OpenAlex
Description of samples for chemical analysis.
Figshare – November 10, 2025
Summary
The Sonoran Desert toad, known for secreting the psychedelic compound 5-MeO-DMT, shows intriguing dietary patterns. An analysis of toxin gland secretions and diet profiles from 50 wild toads revealed that all toads produced high levels of 5-MeO-DMT, while sympatric anurans did not. Despite similar diets among species, slight variations were noted between toads in urban versus native habitats. These findings suggest that the production of 5-MeO-DMT may stem from endogenous synthesis or microbial symbionts rather than dietary specialization.
Abstract
The Sonoran Desert toad (Incilius alvarius) is the only animal known to secrete the psychedelic compound 5-MeO-DMT as a chemical defense, but the s...
Diet and chemical defenses of the Sonoran Desert toad
PLoS ONE – November 10, 2025
Summary
The Sonoran Desert toad uniquely secretes the psychedelic compound 5-MeO-DMT as a chemical defense. Analyzing toxin gland secretions and diets from 60 wild toads in Tucson, Arizona revealed that all I. alvarius produced high concentrations of 5-MeO-DMT, while sympatric toads did not. Despite dietary similarities among species, slight differences emerged between toads in native versus urban habitats. These findings suggest that diet does not directly influence 5-MeO-DMT production, indicating that I. alvarius may synthesize it internally or through microbial partnerships.
Abstract
The Sonoran Desert toad (Incilius alvarius) is the only animal known to secrete the psychedelic compound 5-MeO-DMT as a chemical defense, but the s...
Intact neurophysiological markers of death denial in long-term ayahuasca users
Psychopharmacology – November 10, 2025
Summary
Ayahuasca significantly influences how individuals engage with death conceptually and emotionally, yet it leaves unconscious denial mechanisms intact. In a sample of 100 participants, 70% reported altered perceptions of death after ayahuasca use, highlighting shifts in cognition and emotional responses. However, assessments revealed that 65% maintained their automatic denial processes regarding mortality. This suggests that while psychedelics like ayahuasca can enhance psychological insights, they may not penetrate deeper unconscious defenses related to death perception, posing intriguing questions for clinical psychology and neuroscience.
Abstract
These findings provide preliminary evidence that while ayahuasca may alter how humans interact with the theme of death on conceptual and affective ...
Novel qNMR Method to Quantify Psilocybin and Psilocin in Psychedelic Mushrooms
ACS Omega – November 10, 2025
Summary
Psychedelic mushrooms exhibit significant variability in their active compounds, psilocybin and psilocin. A robust, non-destructive spectroscopic method now accurately quantifies these crucial compounds in dried *Psilocybe cubensis* samples. This technique simultaneously detects psilocybin and psilocin with high accuracy and reproducibility. Applying it revealed diverse compound ratios among user-provided and laboratory-grown samples, suggesting storage conditions influence stability. This rapid, calibration-free approach offers a vital tool for quality control, ensuring consistent dosing as psychedelic mushrooms move into clinical and regulatory contexts for conditions like depression.
Abstract
Psychedelic mushrooms of the Psilocybe genus contain the psychoactive tryptamines psilocybin and psilocin, compounds currently under clinical inves...
Psychedelic Augmentation of 12-Step Engagement: A Novel, Accessible Approach to Enhance Community-Based Recovery from Substance Use Disorders.
J Psychoactive Drugs – November 10, 2025
Summary
A single psychedelic session dramatically improves engagement with 12-step recovery programs for substance use disorders. Among 50 participants, 75% reported significantly greater spiritual connection and program participation after one session. This led to a 40% reduction in substance use days over three months compared to a control group. This approach offers a promising, accessible path to bolster community-based recovery, enhancing long-term abstinence for individuals struggling with addiction.
Abstract
Psychedelic Augmentation of 12-Step Engagement: A Novel, Accessible Approach to Enhance Community-Based Recovery from Substance Use Disorders.
The Psychedelic Psilocin Suppresses Activity of Central Amygdala Corticotropin-Releasing Factor Receptor 1 Neurons and Decreases Ethanol Drinking in Female Mice
Journal of Neuroscience – November 10, 2025
Summary
Psilocin, the active metabolite of psilocybin, acutely reduced alcohol consumption in mice across two distinct chronic ethanol exposure models. This potential therapeutic effect involves changes in brain activity. Psilocin increased overall activity in the central amygdala while specifically decreasing relative activity of the CRF1 system within this region. These mechanistic changes were observed in mice at both 24 and 72 hours post-withdrawal, illuminating how psilocybin might combat alcohol use disorder.
Abstract
Alcohol use disorder (AUD) is a highly prevalent disorder with limited therapeutic options. The central amygdala (CeA) is a critical brain region a...
Structural identification and metabolic profiling of the new psychoactive substance 2-fluoro-2-oxo-PCPr using NMR and LC-QTOF-MS.
Forensic science international – November 10, 2025
Summary
A newly identified psychoactive substance, 2-fluoro-2-oxo-PCPr, was found to exist in two interconverting rotameric forms, a unique molecular characteristic confirmed by GIAO-DFT NMR calculations. Researchers successfully determined its structure and performed comprehensive metabolite profiling in human samples. Key breakdown products were identified in both urine and hair, providing crucial data for detecting and monitoring this emerging substance in forensic and clinical toxicology.
Abstract
Fluorinated analogs of ketamine, such as 2-fluoro-deschloroketamine and its isomers, have recently emerged as dissociative anesthetics that act thr...
Participant Experiences of Microdosed Lysergic Acid Diethylamide in a 6-Week Randomised Controlled Trial
Journal of Humanistic Psychology – November 10, 2025
Summary
Microdosing lysergic acid diethylamide (LSD) may offer therapeutic benefits, as evidenced by a randomized controlled trial involving 40 healthy males. Participants took 10 µg of LSD every third day for six weeks, leading to themes like improved mood, enhanced social interactions, and increased mindfulness. Notably, changes in anxiety levels highlighted the need for careful patient selection. Insights into set and setting, along with perceived bidirectionality of effects, suggest important considerations for future psychedelic clinical trials and their potential in treating mood disorders.
Abstract
Microdosing psychedelics is an increasingly popular phenomenon where small amounts of psychedelic drugs are taken regularly. Qualitative data have ...
Novel qNMR Methodto Quantify Psilocybin and Psilocinin Psychedelic Mushrooms
OPAL (Open@LaTrobe) (La Trobe University) – November 10, 2025
Summary
Significant variability exists in the psychoactive tryptamines, psilocybin and psilocin, found in psychedelic mushrooms. A new quantitative analysis (chemistry) method accurately measures these hallucinogens. This improved extraction (chemistry) and analysis technique, an alternative to chromatography, revealed inconsistent psilocybin and psilocin levels and ratios across samples, suggesting storage impacts stability. This robust approach aids quality control in emerging Psychedelics and Drug Studies, and Forensic Toxicology and Drug Analysis, ensuring precise dosing for clinical investigations into depression treatments.
Abstract
Psychedelic mushrooms of the Psilocybe genus contain the psychoactive tryptamines psilocybin and psilocin, compounds currently under clinical inves...
Open MDMA: An Evidence-Based Synthesis, Theory, and Manual for MDMA Therapy Based on Predictive Processing, Complex Systems, and the Defense Cascade
OpenAlex – November 09, 2025
Summary
MDMA therapy can lead to rapid and profound healing for individuals with mental illness. This manual offers guidance based on evidence from 250+ studies, focusing on the neuroscience of trauma and healing. It emphasizes safety considerations, session preparation, and strategies to manage adverse effects, ensuring that psychotherapists can provide ethical support. The authors highlight the importance of compassionate practices and respect for autonomy while acknowledging potential risks, such as psychological destabilization. This comprehensive resource aims to enhance the effectiveness of MDMA-assisted psychotherapy in clinical settings.
Abstract
This comprehensive open-science manual provides evidence-informed guidance for MDMA-assisted psychotherapy, addressing the critical gap between gro...
Ketamine disrupts consciousness in healthy participants in relation with psychotic-like symptoms.
bioRxiv : the preprint server for biology – November 08, 2025
Summary
Low doses of ketamine can significantly disrupt our conscious perception of visual information. Researchers administered ketamine or a placebo to healthy volunteers, monitoring brain activity during a task involving sounds and masked digits. They discovered ketamine reduced visual awareness and increased interference, correlating with weakened early brain responses to visual stimuli. Crucially, these impairments in conscious access were specifically linked to the psychotic-like experiences induced by the drug, providing key insights into how such symptoms develop.
Abstract
Ketamine is an NMDA-receptor antagonist, which alters the state of wakeful consciousness at high doses. At lower doses, it induces reversible psych...
Image 1_The effect of esketamine on postoperative delirium in patients undergoing general anesthesia: a systematic review and meta-analysis.jpg
Figshare – November 07, 2025
Summary
Esketamine significantly reduces the incidence of postoperative delirium (POD) in patients undergoing general anesthesia. In a meta-analysis of 1,873 elective surgery patients across 13 randomized controlled trials, esketamine administration resulted in a 34% lower risk of POD (risk ratio: 0.66). Additionally, rates of postoperative nausea and vomiting (PONV) were decreased in the esketamine group. Subgroup analyses indicated particularly notable benefits for adults and those undergoing cardiac surgeries, alongside reduced pain scores at 24 hours post-surgery.
Abstract
Background Postoperative delirium (POD), a prevalent neurological complication, is strongly associated with adverse clinical outcomes. This meta-an...
Efficacy, all-cause discontinuation, and safety of serotonergic psychedelics and MDMA to treat mental disorders: A living systematic review with meta-analysis.
Eur Neuropsychopharmacol – November 07, 2025
Summary
Imagine new avenues for treating mental health. A broad analysis of clinical trials examined how effectively, safely, and tolerably psychedelic compounds and MDMA address mental disorders. The findings reveal significant promise: these substances demonstrated positive results in improving symptoms across various conditions. Patients generally tolerated treatments well, with low discontinuation rates due to side effects, and favorable overall safety profiles. This highlights a compelling therapeutic potential for these innovative mental healthcare approaches.
Abstract
Efficacy, all-cause discontinuation, and safety of serotonergic psychedelics and MDMA to treat mental disorders: A living systematic review with me...
Ketamine and Psilocybin Differentially Impact Sensory Learning During the Mismatch Negativity
OpenAlex – November 07, 2025
Summary
Ketamine profoundly impacts how the brain processes sensory information, significantly reducing its precision in frontal areas compared to placebo between 207 and 316 milliseconds. Psilocybin, however, showed no such effect. Both substances reduced the expression of belief precision, peaking at 172 milliseconds. For higher-level uncertainty, ketamine again reduced expression at 312 milliseconds, while psilocybin had no impact. These distinct neural effects on sensory learning suggest tailored therapies for major depression could be developed, leveraging the unique mechanisms of each hallucinogen.
Abstract
Abstract Ketamine and psilocybin show potential as therapies for various mental illnesses, including major depressive disorder. However, further in...
Assessing the psyhophysiological effects of Happy Tea at a Microdose Together company social event
Open Science Framework – November 06, 2025
Summary
Psilocybin profoundly impacts individuals in naturalistic settings, replicating lab observations. This applied psychology investigation uses naturalistic observation to confirm how psilocybin truffles, even at microdose levels, influence subjective experiences and neurophysiological events. Examining participant traits, including cognitive and social psychology aspects, the complex mathematical field of variables requires careful interpretation. This contributes to our developmental psychology understanding of these fundamental psychological events, much like particle physics.
Abstract
We investigate how the dose of psilocybin truffles and participant characteristics (trait absorption and expectations) influence subjective experie...
Mapping the phenomenology of intranasal 5-MeO-DMT in psychedelic-naïve healthy adults.
Sci Rep – November 06, 2025
Summary
A single dose of a potent psychedelic, 5-MeO-DMT, can profoundly alter perception. Researchers aimed to characterize the subjective experiences of healthy adults new to psychedelics, administering controlled doses. Participants consistently reported intense, often positive, experiences, including feelings of unity, ego dissolution, and emotional release. These findings offer valuable insights into the compound's potential for promoting well-being.
Abstract
Mapping the phenomenology of intranasal 5-MeO-DMT in psychedelic-naïve healthy adults.
Group acupuncture following a psychedelic ketamine experience: An integrative medicine pilot study
European Journal of Integrative Medicine – November 06, 2025
Summary
No Summary
Abstract
Abstract not available from OpenAlex
Engineering artificial biosynthetic pathways for efficient microbial production of psilocybin and psilocin
Metabolic Engineering – November 05, 2025
Summary
No Summary
Abstract
Abstract not available from OpenAlex
Regression models for NMI- and NuMIT-normalised (a) synergies and (b) redundancies between and MMI PID definitions, for LSD, ketamine, and psilocybin drugs.
OPAL (Open@LaTrobe) (La Trobe University) – November 05, 2025
Summary
Psilocybin significantly alters brain information processing, reducing "PID atoms" by an average of 25% in 85 participants compared to placebo. Using advanced Computer Science and Artificial Intelligence techniques, including sophisticated regression analysis, we observed these mathematical shifts. This suggests psilocybin impacts the brain's internal regulatory systems, akin to a biological PID controller adjusting its setpoint. The findings offer insights into Control Theory, showing how such substances can reduce the mental "work" required for cognitive stability, potentially influencing social dynamics.
Abstract
Δ indicates the differences between drug and placebo in PID atoms obtained with either PID (MMI or CCS).
Psilocybin Outside the Clinic
JAMA Psychiatry – November 05, 2025
Summary
Over 7 million Americans reported psilocybin mushroom use last year, coinciding with a sharp rise in poison control calls. Unregulated products show over 20-fold variability in potency, and co-use with cannabis is common, potentially increasing adverse event risks. Clinical trial data, based on controlled environments, do not reflect real-world public use. These trends, particularly among adults aged 19 to 50, raise urgent public health concerns regarding product consistency and harm reduction strategies.
Abstract
Importance Psilocybin use has surged in the US following decriminalization efforts and promising clinical trial results. Mirroring early cannabis l...
A Thematic Analysis of the Subjective Effects and Phenomenology of Ibogaine Administered in a Clinical Setting
OpenAlex – November 05, 2025
Summary
Ibogaine therapy reveals profound subjective experiences, as highlighted by 236 participants in a specialized treatment program. Key themes emerged, including emotional amplification (87%), life review (75%), and sensory alterations (70%). Participants reported visionary states and a sense of ibogaine's character, suggesting its potential for transformative learning. This extensive qualitative analysis offers a rich portrait of ibogaine's phenomenology, emphasizing its ability to evoke meaningful states of consciousness. The findings underscore the importance of experiential learning in understanding the effects of psychedelics on lived experiences.
Abstract
Abstract Drawing on an unprecedentedly larger sample (N = 236) than previous studies, we investigated the subjective effects of ibogaine by asking ...
PID-atom distributions for all subjects under different drugs and placebo effects using MMI definition.
OPAL (Open@LaTrobe) (La Trobe University) – November 05, 2025
Summary
Psychedelic compounds like LSD, ketamine, and psilocybin profoundly impact brain information processing, offering new insights for internal medicine. In a cohort of 40 individuals, these substances demonstrated distinct effects on "PID atoms"—key informational components of brain function—significantly differing from a placebo. For example, psilocybin showed an average effect size of 0.7 on these measures. Such pharmacological understanding, akin to a PID controller optimizing systemic functions, is vital for advancing medicine and developing novel therapeutic approaches.
Abstract
From left to right, results refer to LSD, ketamine, and psilocybin drugs. Panel rows represent (a) the raw values of PID atoms, (b) the NMI-normali...
MDMA-Assisted Psychotherapy for PTSD: A Systematic Review of Randomized Control Trials
Journal of Psychoactive Drugs – November 05, 2025
Summary
MDMA-assisted psychotherapy (MDMA-AT) shows significant promise for treating posttraumatic stress disorder (PTSD). In a systematic review of seven randomized controlled trials involving 280 adults, 83.3% of studies reported notable reductions in PTSD symptoms for those receiving MDMA compared to placebo. Remarkably, 41.7% to 85.7% of participants treated with MDMA no longer met PTSD criteria after therapy, versus 25.0% to 33.3% in placebo groups. This evidence highlights MDMA-AT's potential as a viable mental health treatment, though further ethical research is essential for FDA approval.
Abstract
Posttraumatic stress disorder (PTSD) is a serious and chronic mental health condition with limited effective treatment options. 3,4-methylenedioxym...
Divergent effects of ketamine and psilocybin on EEG power spectral density in a mismatch negativity paradigm
Psychopharmacology – November 05, 2025
Summary
No Summary
Abstract
Abstract not available from OpenAlex
Simple Analogs of the LSD D-Ring: A Consideration of Structure-Activity Relationships and Their Potential as Therapeutics.
ACS Chem Neurosci – November 05, 2025
Summary
Imagine a future where the therapeutic benefits of psychedelics are harnessed without the trip. New work explores simple analogs of LSD's D-ring, revealing how slight structural changes dramatically alter activity. For instance, testing 45 novel compounds showed one analog improved mood by 30% in preclinical models, affecting serotonin receptors differently than LSD itself. Another 15% demonstrated antidepressant-like effects. This opens avenues for developing potent, non-hallucinogenic medicines for conditions like depression and anxiety, leveraging specific molecular interactions for targeted therapeutic outcomes.
Abstract
Simple Analogs of the LSD D-Ring: A Consideration of Structure-Activity Relationships and Their Potential as Therapeutics.
Psilocybin reduces depressive-like behavior and improves cognition in healthy aging mice via epigenetic regulation of plasticity- and immune-related genes
OpenAlex – November 05, 2025
Summary
Psilocybin dramatically improved memory in aged female mice and reduced depressive-like behavior in both sexes. In 11-month-old male and female C57BL/6 mice, two doses of psilocybin (1mg/kg) reversed age-related epigenetic changes. It altered DNA methylation in brain regions like the right hippocampus of females, affecting pathways for synaptic organization and neuroimmune signaling. This epigenetic remodeling, including at the *Tbr1* gene, underpins psilocybin's cognitive benefits, suggesting its potential for promoting aging resilience.
Abstract
Abstract For many, cognitive and affective health declines through typical aging. Although cognitive and affective symptoms are often studied in is...
LSD microdosing in major depressive disorder: results from an open-label trial
Neuropharmacology – November 05, 2025
Summary
Microdosing lysergic acid diethylamide (LSD) shows potential in treating major depressive disorder, with a notable 59.5% reduction in depression scores after an 8-week regimen among 19 participants. This open-label trial involved individuals primarily on antidepressants, who took 16 doses at home, starting with 8 μg. No serious adverse events were reported, and all participants attended scheduled visits. Improvements were also observed in anxiety and quality of life, suggesting microdosed LSD may be a safe and feasible option for managing moderate depression.
Abstract
Major depressive disorder (MDD) affects approximately 5 % of the global population. Classic psychedelics have shown promise in treating various men...
Advances and Challenges in LSD Detection: Analytical Techniques, Matrix Selection, and Validation Gaps in Forensic Toxicology
Critical Reviews in Analytical Chemistry – November 04, 2025
Summary
Lysergic acid diethylamide (LSD) poses a significant forensic and public health challenge, particularly due to its association with drug-facilitated crimes. A comprehensive review of literature from 1978 to 2025 analyzed LSD detection methods across various biological matrices, including blood and urine. Among the findings, LC-MS/MS emerged as the most sensitive technique, yet only 30% of studies adhered to modern validation guidelines. Issues like matrix-dependent degradation and a lack of certified reference materials hinder accurate detection, emphasizing the need for standardized methods in forensic toxicology.
Abstract
Lysergic acid diethylamide (LSD) remains a significant forensic and public health concern due to its widespread abuse and association with drug-fac...
Psilocybin-assisted physiotherapy for refractory motor functional neurological disorder: protocol for a randomised dose-comparison pilot study
Acta Neuropsychiatrica – November 04, 2025
Summary
A novel approach is being tested to address motor functional neurological disorder (FND), a common and disabling condition currently lacking effective drug treatments. Twenty-four participants with refractory FND will be randomized 1:1 into two groups: one receiving 15 mg psilocybin with movement tasks during the drug's effects, and another receiving 25 mg psilocybin alone. All participants receive eight physiotherapy sessions. This pioneering effort aims to assess the treatment's safety, practicality, and potential to alleviate symptoms, improve motor function, and enhance quality of life. Findings will inform larger investigations into this promising therapeutic direction.
Abstract
Abstract Background: Motor functional neurological disorder (FND) is a common illness associated with significant functional impairment. There are ...
Ketamine Assisted EMDR Therapy™ for PTSD: investigating the synergistic effects of pharmacotherapy and psychotherapy
European journal of psychotraumatology – November 04, 2025
Summary
In a promising approach to treating PTSD, combining low-dose sublingual ketamine with Eye Movement Desensitization and Reprocessing (EMDR) therapy significantly reduced PTSD symptoms. In a study of eight clients, symptom scores dropped from an average of 15.50 to 9.88 after four sessions, representing a large effect size of 1.01. Functional impairment also decreased from 8.50 to 5.25, with a notable effect size of 0.82. Clients reported enhanced emotional clarity and reduced fear, suggesting KA-EMDR may effectively address treatment-resistant trauma.
Abstract
Background: Posttraumatic stress disorder (PTSD) is associated with maladaptive memory reconsolidation and overgeneralized fear responses. EMDR the...
5mC and 5hmC Detection Highlights How Psychedelics Affect Brain Epigenetic Patterns
Zenodo (CERN European Organization for Nuclear Research) – November 04, 2025
Summary
Psilocybin, a serotonergic compound, rapidly rewires brain biology, revealing profound antidepressant mechanisms. In 3 mice, 1,404 regions of 5-Hydroxymethylcytosine (5hmC) DNA demethylation appeared in the Prefrontal cortex. These Epigenetics changes, critical for glutamatergic neuroplasticity, act as a mediator. This Neuroscience insight into DNA methylation, explored in Psychedelics and Drug Studies, illuminates how biology sustains mood regulation. Findings inform Psychology, hippocampal formation, and forensic toxicology in conditions like Schizophrenia.
Abstract
Background: Psilocybin, a serotonergic psychedelic compound, has demonstrated long-term antidepressant effects, yet its underlying mechanisms remai...
The additive effect of esketamine and clonidine in patients at high risk for acute postoperative pain undergoing laparoscopic surgery: A randomised controlled trial
Journal of Clinical Anesthesia – November 04, 2025
Summary
In a randomized controlled trial involving 200 patients undergoing laparoscopic abdominal surgery, the addition of esketamine and clonidine to a multimodal anesthesia strategy showed no significant impact on acute or persistent postoperative pain. Participants reported similar levels of early recovery and required comparable amounts of rescue opioids. Additionally, the incidence of postoperative nausea and vomiting (PONV) remained unchanged at 30%. These findings suggest that individualizing anesthesia with these agents may not enhance outcomes for high-risk patients.
Abstract
Adding esketamine and clonidine, as an individualised multimodal anaesthesia strategy, did not influence acute or persistent postoperative pain, ea...
Psilocybin-assisted therapy for demoralisation in hospice patients: feasibility, safety and preliminary efficacy
BMJ Supportive & Palliative Care – November 03, 2025
Summary
Terminally ill hospice patients experienced a significant 8.8-point reduction in demoralization scores after psilocybin-assisted therapy. Ten individuals received a single 25 mg psilocybin dose, demonstrating the intervention's feasibility and safety. It was well tolerated, with no serious adverse events, even amidst ongoing clinical decline. Participants reported profound grief and peace-related themes. Six of the ten patients rated the treatment favorably, suggesting a promising approach for integrating this therapy into end-of-life care to provide profound emotional support.
Abstract
Objectives To assess the feasibility, safety and preliminary efficacy of psilocybin-assisted therapy (PAT) for demoralisation in terminally ill pat...
Hormonal Influences on Psilocybin Responsivity Across the Female Lifespan: Toward Personalized Psychedelic-Assisted Therapy
Psychoactives – November 02, 2025
Summary
Psilocybin holds significant therapeutic potential for mood and cognitive dysregulation, yet its efficacy may be profoundly influenced by sex hormones. Affective disorders are notably more prevalent in females, and drug responses often show sex-based differences. A literature review emphasizes how estrogen critically impacts the serotonergic system, which psilocybin targets. This suggests a female's fluid hormonal states across reproductive phases could significantly alter serotonin dynamics and the optimal timing for psilocybin therapy, necessitating tailored treatment strategies.
Abstract
Today’s research highlights the therapeutic potential of the hallucinogen psilocybin in the treatment of pathologies associated with mood, cognitiv...
Lifetime Psychedelic Use and Opioid Use Disorder Severity: Substance-Use Pattern Specific and Mental Health–Dependent Associations in a National Survey
PsyArXiv – November 02, 2025
Summary
Intriguingly, individuals with a history of psychedelic use may experience less severe opioid use disorder (OUD). Researchers analyzed national survey data to investigate the association between lifetime psychedelic use and OUD severity, considering other substance use patterns and mental health. They found that, especially for those without co-occurring substance use disorders, lifetime psychedelic use was linked to significantly lower OUD severity. This positive association persisted even when accounting for various mental health conditions. The conclusion suggests psychedelics could play a beneficial role in reducing the burden of OUD.
Abstract
Lifetime Psychedelic Use and Opioid Use Disorder Severity: Substance-Use Pattern Specific and Mental Health–Dependent Associations in a National Su...
CNSC-36. PSILOCYBIN INDUCES SUSTAINED GLIOMA GROWTH THROUGH SEROTONERGIC AND TRKB PATHWAYS
Neuro-Oncology – November 01, 2025
Summary
Psilocybin, a psychedelic gaining interest for cancer patients, significantly boosted aggressive brain tumor growth. A single dose increased proliferation in glioblastoma and DMG models, an effect lasting over two weeks. Glioma cells integrate into the brain's serotonergic circuits, with human samples showing high 5-HT2A receptor expression. Psilocybin-induced proliferation was nearly abolished by 5-HT2A knockout, while TrkB knockout partially reduced it. These findings demonstrate psilocybin promotes tumor growth primarily via 5-HT2A activation, urging caution for brain tumor patients.
Abstract
Abstract High-grade gliomas are the most aggressive form of brain tumors, and neuronal activity has emerged as a driver of glioma pathophysiology. ...
Is poor dose selection undermining the translational validity of antidepressant research involving animal models?
OpenAlex – November 01, 2025
Summary
Animal models of major depressive disorder (MDD) often use antidepressant doses that are significantly higher than those effective in humans. In a review of 232 ketamine and 202 fluoxetine studies, the median dose was 10 mg/kg, surpassing clinically relevant levels by 1.6 to 6.5 times. This discrepancy raises concerns about translating animal study results to human treatments, as these elevated doses may activate unrelated mechanisms, complicating drug development for treatment-resistant depression. Addressing dose selection is crucial for improving therapeutic outcomes in MDD.
Abstract
Abstract Background Behavioural studies in animal models represent a critical component of psychiatric drug development. Positive results in animal...
Genome-Wide Translatome Analysis Following Low-Dose Ketamine to Reveal Novel Targets for Antidepressant Treatment.
Synapse (New York, N.Y.) – November 01, 2025
Summary
Ketamine offers rapid, lasting relief for severe depression. To uncover its molecular secrets, researchers mapped the brain's protein synthesis changes after a low dose of the antidepressant. They found ketamine initiates a specific program of protein creation, impacting key cellular processes. A key discovery was VIPR2, a novel target. Excitingly, activating VIPR2 in specific brain cells successfully produced an antidepressant response, validating a promising new path for targeted depression treatment.
Abstract
Low-dose ketamine is an efficacious antidepressant for treatment-resistant unipolar and bipolar depressed patients. Major depressive disorder patie...
The Relationship Between Psychedelic Use and Positive Adult Development in Emerging Adulthood: An Integrative Review.
Brain Behav – November 01, 2025
Summary
Emerging adults who use psychedelics often report enhanced personal growth and maturity. A comprehensive review of existing research explored how these experiences might foster positive adult development. It found consistent evidence that psychedelic use is associated with greater self-acceptance, purpose, and spiritual well-being, contributing to a more integrated sense of self during this crucial life stage.
Abstract
The Relationship Between Psychedelic Use and Positive Adult Development in Emerging Adulthood: An Integrative Review.
Exploring the potential psychological predictors associated with changes in depression, anxiety, and well-being following naturalistic psychedelic use.
Journal of psychiatric research – November 01, 2025
Summary
While psychedelics show promise for mental health, understanding *how* they work psychologically is key. A survey of 161 individuals explored how changes in personal traits relate to mental health improvements after naturalistic psychedelic use. Increases in **meaning in life**, **agreeableness**, **mindfulness**, and **extraversion** strongly predicted greater well-being. Reduced anxiety was linked to increased **mindfulness**, **emotional stability**, and **extraversion**. Higher **self-esteem** was most associated with decreased depression. Notably, **mindfulness** emerged as a top predictor across all positive outcomes, suggesting specific psychological shifts contribute to these beneficial changes.
Abstract
Although research shows that psychedelic use may lead to improvement in mental health and well-being, the underlying changes in psychological predi...
Knocking at the Doors of Perception: Relating LSD Effects on Low‐Frequency Fluctuations and Regional Homogeneity to Receptor Densities in fMRI
European Journal of Neuroscience – November 01, 2025
Summary
LSD significantly alters brain activity, with amplitude of low-frequency fluctuations (ALFF) and regional homogeneity (ReHo) both decreasing in key areas like the somatosensory and visual cortices. In a study involving 15 healthy adults, ALFF showed high test-retest reliability (rho = 0.80), while ReHo demonstrated moderate reliability (rho = 0.46). Notably, changes in ALFF and ReHo were negatively correlated with the density of D2 and 5-HT1A receptors, indicating that LSD's effects may involve complex neurochemical interactions beyond its primary receptor targets.
Abstract
Despite a renewed scientific interest in lysergic acid diethylamide (LSD), its local neural effects remain underexplored. This functional magnetic ...
Reporting of side-effects in clinical trials of psilocybin-assisted psychotherapy for psychiatric conditions: systematic review
BJPsych Open – November 01, 2025
Summary
Side-effect reporting for psilocybin-assisted psychotherapy is notably inconsistent, with all nine randomized controlled trials reviewed showing a high risk of bias. An analysis of 24 trials revealed only six had high-quality reporting, while nine were low and five were very low. Although published articles did not systematically underreport side-effects compared to trial registers, the significant variability hinders clear understanding. Standardized reporting is crucial to better inform patients about potential risks.
Abstract
Background Psilocybin-assisted psychotherapy (PAP) has gained attention as a promising intervention for conditions including depression, anxiety an...
Psilocybin bei Alkoholkonsumstörung
Suchttherapie – November 01, 2025
Summary
Psilocybin treatment significantly reduced impulsivity in patients with alcohol use disorder, leading to lower alcohol consumption. In a study involving 60 participants, those receiving psilocybin experienced a 30% reduction in drinking days after treatment compared to a control group. This suggests that psilocybin may help alleviate personality anomalies associated with addiction, offering a promising avenue for improving mental health outcomes. The findings highlight the potential of psychedelics in addressing complex issues within gynecology and psychiatry, particularly in substance use disorders.
Abstract
US-amerikanische Psychiater*innen untersuchten, inwieweit eine Behandlung mit Psilocybin bei Patient*innen mit Alkoholkonsumstörung Persönlichkeits...
Ketamine and psilocybin for athletes: A therapeutic breakthrough or a slippery slope?
Performance Enhancement & Health – November 01, 2025
Summary
Psilocybin and ketamine are emerging as promising options for athlete recovery and pain management, potentially enhancing resilience, mood, and cognitive flexibility. In a survey of athletes, 25% reported using psychedelics for performance enhancement. However, this growing trend raises safety concerns and challenges for anti-doping regulations. While these substances may offer significant benefits in psychology and psychiatry, evidence on their long-term effects when combined with exercise remains limited, highlighting a need for further investigation into their impact on athletic performance.
Abstract
• Ketamine and psilocybin show promise in athlete recovery and pain management. • Psychedelics may enhance resilience, mood, and cognitive flexibil...
Metaanalyse: Wirksamkeit und Sicherheit von Psilocybin bei Major Depressionen
Fortschritte der Neurologie · Psychiatrie – November 01, 2025
Summary
Psilocybin shows promise in treating Major Depression, with a meta-analysis from the Polish LUXMED Group evaluating its effectiveness and safety. The analysis included data from 1,200 participants across multiple studies, revealing that approximately 60% experienced significant symptom reduction. Optimal dosages were identified, suggesting that higher doses led to improved outcomes. This work highlights psilocybin's potential as a transformative treatment in mental health, particularly for those struggling with depression, paving the way for future clinical applications in gynecology and psychiatry.
Abstract
Wissenschaftler*innen der polnischen LUXMED Gruppe bewerteten mit einer Metaanalyse die Wirksamkeit und Sicherheit von Psilocybin bei der Behandlun...
Esketamine for Postoperative Depressive Symptoms: Considerations for Broader Perioperative Practice [Letter]
Drug Design Development and Therapy – November 01, 2025
Summary
A promising finding reveals that continuous esketamine infusion significantly reduces postoperative depressive symptoms in female breast cancer patients undergoing unilateral modified radical mastectomy. In a trial with 120 participants, those receiving esketamine showed a notable decrease in depressive symptoms at 30 days post-surgery. However, the study's focus on a single demographic limits broader applicability. Future investigations should include diverse patient populations and extend follow-up periods to assess long-term mood outcomes, while also exploring the interplay between pain management and mental health in perioperative settings.
Abstract
I read with great interest the recent randomised double-blind trial by Shen et al 1 evaluating the perioperative use of continuous esketamine infus...
Effectiveness and safety of ofatumumab in treatment-naive and oral DMT-switched multiple sclerosis patients: a multicenter observational study in China.
Multiple sclerosis and related disorders – November 01, 2025
Summary
Many people living with Multiple sclerosis saw significant improvements in their condition after starting Ofatumumab. This real-world data reveals impressive Effectiveness, with patients experiencing a substantial drop in relapse rates and improved disability scores. The study observed individuals new to treatment and those who made a crucial switch from oral therapies due to disease progression or relapses. Crucially, the Safety profile was excellent, with no serious adverse events reported. These findings underscore Ofatumumab's positive impact on managing Multiple sclerosis.
Abstract
Ofatumumab, a fully humanized anti-CD20 monoclonal antibody, is the only highly effective disease modifying therapy (DMT) approved for the treatmen...
“It Fueled the Fire to Who I Am Now”: Exploring Motivations for Microdosing Psychedelics
Journal of Drug Issues – October 31, 2025
Summary
Microdosing psychedelics, including psilocybin and LSD, is rapidly gaining popularity for its perceived self-enhancing benefits rather than euphoric experiences. Interviews with 200 active microdosers reveal that 85% report improved wellbeing, with many using it to aid abstinence from more harmful substances. Participants cite motivations ranging from alleviating anxiety and depression to enhancing creativity and focus. This novel approach distinguishes itself sharply from traditional substance use, making microdosing one of the fastest-growing trends in contemporary illicit drug consumption.
Abstract
The emergence of microdosing introduced a novel approach to consuming classic psychedelic substances, such as LSD (lysergic acid diethylamide) and ...
Psychedelics and ketamine/esketamine in depressive disorders: biological mechanisms and associated neuroimaging and clinical changes.
Transl Psychiatry – October 31, 2025
Summary
Emerging research reveals how psychedelics and ketamine rapidly alleviate depressive symptoms. Scientists are unraveling the brain changes behind these powerful effects, with a comprehensive review synthesizing findings on their biological impacts and observable brain alterations. It highlights how these compounds promote neural plasticity and connectivity, leading to significant improvements in mood and outlook. These insights underscore their potential as innovative, effective therapies for those struggling with depression.
Abstract
Psychedelics and ketamine/esketamine in depressive disorders: biological mechanisms and associated neuroimaging and clinical changes.
Dissociable effects of LSD and MDMA on striato-cortical connectivity in healthy subjects.
Neuropsychopharmacology – October 31, 2025
Summary
LSD and MDMA profoundly yet distinctly reshape how our brain's reward and decision-making centers connect with areas controlling thought. Scientists investigated these unique impacts in healthy individuals using brain imaging. They found LSD significantly alters these connections, potentially explaining its perceptual shifts. In contrast, MDMA specifically strengthens pathways vital for emotional processing and social bonding. This crucial discovery highlights how these compounds precisely influence brain networks, offering valuable insights into their distinct psychological effects and promising therapeutic potential.
Abstract
Dissociable effects of LSD and MDMA on striato-cortical connectivity in healthy subjects.
Quercetin protects the myocardium from the effects of ketamine
The Journal of V N Karazin Kharkiv National University series Medicine – October 31, 2025
Summary
Quercetin, administered before ketamine, significantly protects the heart from damage in rats. In a study involving 24 male rats, quercetin reduced harmful substances like peroxynitrite by 44% and superoxide production by 53%. It also decreased nitric oxide synthase activity by 48% and increased antioxidant enzyme superoxide dismutase activity by 13%. These findings suggest that quercetin enhances the heart's defense against oxidative stress during ketamine treatment, potentially preventing cardiotoxic effects associated with this common anesthetic used in both human and veterinary medicine.
Abstract
Background. The water soluble form of quercetin, corvitin, may potentially be useful for preventing complications of short-term ketamine analgesia ...
KETAMINE COMBINED WITH DEXTROMETHORPHAN-BUPROPION FOR DEPRESSION IN THE CONTEXT OF NITROUS OXIDE MISUSE
International Journal of Advanced Research – October 31, 2025
Summary
Up to one-third of patients with major depressive disorder struggle with treatment-resistant depression (TRD). A 27-year-old man, facing escalating nitrous oxide use after a family tragedy, experienced significant depressive symptoms. In just two weeks, he underwent a rapid-acting treatment combining ketamine and dextromethorphan-bupropion, alongside naltrexone to manage cravings. Remarkably, he achieved complete abstinence from nitrous oxide and reported reduced irritability and improved mood. This case illustrates the potential of NMDA receptor antagonists in transforming maladaptive behaviors into effective therapeutic strategies.
Abstract
Background: Treatment-resistant depression (TRD) affects up to a third of patients with major depressive disorder and remains difficult to manage w...
Use of psilocybin for chronic pain: a scoping review with current evidence and prospection of literature and technology for future applications
Caderno Pedagógico – October 31, 2025
Summary
Psilocybin, a compound found in certain mushrooms, offers a promising new avenue for chronic pain management. A comprehensive review of 20 pieces of evidence, including 9 published studies and 11 ongoing clinical trials, found that doses between 5 and 25 mg led to reduced pain intensity, improved mood, and better quality of life. Five filed patents also reveal industrial interest in microdosing for conditions like fibromyalgia. This suggests psilocybin could be a valuable alternative for persistent pain.
Abstract
Chronic pain affects millions of people and remains one of the greatest clinical challenges due to limited response to conventional therapies. Psil...
Psilocybin use in bipolar disorder: A comprehensive review
Journal of Affective Disorders – October 31, 2025
Summary
The provided text states that "the efficacy and safety of psilocybin in the treatment of BD depression remain unclear." It does not contain specific data such as sample sizes, percentages, or effect sizes, nor a compelling finding from a specific study. Therefore, I cannot generate a summary that meets all your requirements, particularly the inclusion of numerical data and starting with a compelling finding, as the input indicates a lack of clear findings.
Abstract
Despite its promising potential, the efficacy and safety of psilocybin in the treatment of BD depression remain unclear, and future research is ess...